Insulinosecretion in type 2 diabetes: Clinical aspects

Diabetes and Metabolism

Volumn 28, Issue 6 SUPPL., 2002, Pages

  Boitard, C ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b Hop Cochin Saint Vincent de Paul ^*  (France)

Author keywords

Autoantibodies; Genetics; Insulin secretion tests; Type 1 diabetes; Type 2 diabetes; cell function

Indexed keywords

INSULIN;

AUTOIMMUNE DISEASE; CONFERENCE PAPER; HUMAN; HUMAN CELL; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL;

EID: 17144454964     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. Del Prato S, Tiengo A. The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus. Diabetes Metab Res Rev, 2001, 17, 164-174.
2. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol, 1979, 237, E214-E223.
3. Waldhausl W. The glucose clamp technique. In Current Topics in Diabetes Research. Belfiore F, Bergman RN, and Molinatti GM, Eds. Basel, Switzerland, S. Karger, 1993, p. 24-31.
4. Mitrakou A, Vuorinen-Markkola H, Raptis G, et al. Simultaneous assessment of insulin secretion and insulin sensitivity using a hyperglycaemic clamp. J Clin Endocrinol Metab, 1992, 75, 379-382.
5. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Tumer RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia, 1985, 28, 412-419.
6. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care, 1999, 22, 1462-1470.
7. Stumvoll M, Mitrakou A, Pimenta W, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care, 2000, 23, 295-301.
8. Philipps DIW, Clark PM, Hales CN, Osmod C. Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabetic Med, 1994, 11, 286-292.
9. Belfiore F, Iannello S, Volpicelli G. Insulin sensitivity indices calculated from basal and OGTT-induced insulin, glucose and FFA levels. Mol Genet Metab, 1998, 63, 134-141.
10. Hosker JP, Matthews DR, Rudenski AS, et al. Continuous infusion of glucose with model assessment: measurement of insulin resistance and beta-cell function in man. Diabetologia, 1985, 28, 401-411.
11. Bingley PJ, Colman P, Eisenbarth GS, et al. Standardization of IVGTT to predict IDDM. Diabetes Care, 1992, 15, 1313-1316.
12. Piatti PM, Monti LD, Caumo A, et al. The continuous low dose insulin and glucose infusion test: a simplified and accurate method for the evaluation of insulin sensitivity and insulin secretion in population studies. J Clin Endocrinol Metab, 1995, 80, 34-40.
13. Scheen AJ, Castillo MJ, Lefebvre PJ. Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: Methodological aspects and clinical applications. Diabetes Metab, 1996, 22, 397-406.
14. Luzi L, DeFronzo RA. Effect of loss of first phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. Am J Physiol, 1989, 257, E241-E246.
15. Mitrakou A, Kelley D, Mohan M, et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med, 1992, 326, 22-29.
16. Hermans MP, Levy JC, Morris RJ, Turner RC. Comparison of tests of β-cell function across a range of glucose tolerance from normal to diabetes. Diabetes, 1999, 48, 1779-1786.
17. Castillo MJ, Scheen AJ, Lefebvre PJ. Modified glucagon test allowing simultaneous estimation of insulin secretion and insulin sensitivity: application to obesity, insulin-dependent diabetes mellitus, and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab, 1995, 80, 393-399.
18. Byrne MM, Sturis J, Polonsky KS. Insulin secretion and clearance during low-dose graded glucose infusion. Amer J Physiol-Endocrinol Met, 1995, 268, 21-27.
19. Horton V, Stratton I, Bottazzo GF, et al. Genetic heterogeneity of autoimmune diabetes: age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43). Diabetologia, 1999, 42, 608-616.
20. Groop L, Groop PH, Koskimies S. Relationship between β-cell function and HLA antigens in patients with type 2 (non insulin-dependent) diabetes. Diabetologia, 1986, 29, 757-760.
21. Rich SS, French LR, Sprafka JM, Clements JP, Goetz FC. HLA-associated susceptibility to type 2 (non insulin-dependent) diabetes mellitus: the Wadena City Health study. Diabetologia, 1993, 36, 234-238.
22. Tuomilheto-Wolf E, Tuomilehto J, Hitman GA, et al. Genetic susceptibility to non-insulin dependent diabetes mellitus and glucose intolerance are located in HLA region. British Med J, 1993, 307, 155-159.
23. Groop L, Mietinen A, Groop PH, Meri S, Koskimies S, Bottazzo GF. Organ-specific autoimmunity and HLA-DR antigens as markers for β-cell destruction in patients with type II diabetes. Diabetes, 1988, 37, 99-103.
24. Gottsäter A, Landin-Olsson M, Lemmark A, Fernlund P, Sundkvist G. Islet cell antibodies are associated with β-cell failure also in obese adult onset diabetic patients. Acta Diabetol, 1994, 31, 226-231.
25. Gottsäter A, Landin-Olsson M, Lemmark A, Sundkvist G, Femlund P. β-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care, 1993, 16, 902-910.
26. Niskanen LK, Tuomi T, Karjalainen J, Groop LC, Uusitupa MIJ. GAD antibodies in NIDDM. Diabetes Care, 1995, 18, 1557-1565.
27. Rowley MJ, Mackay IR, Chen QI, Knowles WJ, Zimmet PZ. Antibodies to glutamic acid decarboxylase discriminate major type of diabetes mellitus. Diabetes, 1992, 41, 548-551.
28. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes, 1993, 42, 359-362.
29. UKPDS Group. Clinical values of autoantibodies to islet cell cytoplasm and glutamic acid decarboxylase in predicting insulin requirement in patients with newly diagnosed NIDDM at different ages. Lancet, 1997, 350, 1288-1293.
30. Tuomi T, Carlsson AL, Li H, et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes, 1999, 48, 150-157.
31. Turner RC, Cull CA, Frighi V, Holman R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA, 1999, 281, 2005-2012.